RSS

dual amylin calcitonin receptor agonists (DACRAs)

The collaboration between Eli Lilly and Company and KeyBioscience will focus on developing a potential new class of treatments for metabolic disorders, such as type 2 diabetes, called dual amylin calcitonin receptor agonists (DACRAs) more

News